Generex Biotechnology to Host Conference Call to Discuss Presentations Presented At the 62nd Annual American Diabetes Association, ADA, Meeting in San Francisco

Business Wire, June 18, 2002

Business Editors & Health/Medical Writers

TORONTO--(BUSINESS WIRE)--June 18, 2002

Thursday, June 20th at 1:30pm EDT

Generex Biotechnology Corporation (Nasdaq NM:GNBT), a leader in the area of buccal drug delivery, today announced that it will host a conference call on Thursday, June 20th to discuss presentations presented at the American Diabetes Association's 62nd Annual Scientific Sessions last weekend in San Francisco.

Date:  Thursday, June 20, 2002
Time:  1:30pm EDT
Participant Dial-in #:                      800-348-6433
International callers, dial:                212-271-4760

The replay of the conference call will be available for 24 hours by dialing 800-633-8284. International callers should dial 858-812-6440. The reservation # is 20699485.

This call is being webcast by CCBN and can be accessed at Generex's web site at www.generex.com.

The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investor can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network such as America Online's Personal Finance Channel, Fidelity Investments(R) (Fidelity.com) and others. Institutional investors can access the call via CCBN's password protected event management site, StreetEvents (www.streetevents.com). StreetEvents allows institutional investors to identify, organize, and track the hundreds of conference calls that occur each day during earnings season, to download events of interest to their Outlook calendar, and to RSVP to events online.

About Generex:

Generex is engaged in the research and development of drug delivery systems and technology. To date, it has focused on developing a platform technology for the buccal delivery - delivery to the oral cavity for absorption through the inner mouth mucosa - of drugs that historically have been administered only by injection. Generex's buccal delivery technology has application to a large number of drugs. The company presently is pursuing the development of a buccal insulin product under an agreement with Eli Lilly & Company and is pursuing the development of a buccal morphine product under a business venture with Elan Corporation.